Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.

Welcome to this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, ...

Analysts and investors have been awaiting more proof that Recursion Pharma’s extensive and homegrown datasets can offer drug discovery platforms a speed-to-clinic edge. A $50 million investment the ...

We recently published 10 Big Names Crushing the Market. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the ...

This week, my colleagues and I scheduled 30 minutes to talk with Mark Cuban for “The Readout LOUD” podcast. The conversation ...

SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower Wednesday after the company reported mixed fourth-quarter financial results. What Happened: Recursion reported fourth-quarter ...